Udfaldet for moder og foster, men de kliniske afprøvninger havde ikke statistisk styrke nok til at udelukke en mulig forskel.
Fetal and maternal outcome did apparently not differ between the atosiban and the β -agonist group, but the clinical studies were not powered enough to rule out a possible difference.